Jia Han

Jia Han

Auto-generated profile, based on publicly available information

Jia Han

Department of Anesthesiology, Deyang People's Hospital, Deyang, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2026 in JMIR Research Protocols
Verified
Journal Article
Open access
YSYuHang Shou
YuHang Shou
JLJianSheng Luo
JianSheng Luo
XZXianJie Zhang
XianJie Zhang
WZWenHu Zhai
WenHu Zhai
JHJia Han
Jia Han
Background: Hysteroscopy, the gold standard for diagnosing and treating intrauterine pathologies, has shown substantial increase in its adoption in clinical practice. Nevertheless, early postoperative pain and opioid-related adverse effects remain critical determinants of recovery quality. Oliceridine—a novel G protein-biased μ-opioid receptor agonist—demonstrates an improved therapeutic range over conventional opioids in preliminary studies. Objective: This study aims to evaluate whether oliceridine enhances recovery quality while reducing opioid-related complications compared to sufentanil in patients undergoing hysteroscopy under general anesthesia. Methods: This single-center randomized controlled trial will enroll 120 patients undergoing hysteroscopy under general anesthesia with 1:1 randomization to sufentanil- or oliceridine-based analgesia. The primary outcome is early recovery quality assessed by the 15-item Quality of Recovery scale at 24 hours after the surgery, while secondary outcomes include hemodynamic fluctuations during induction, total intraoperative opioid consumption and supplemental bolus frequency, proportion requiring vasoactive agents, incidence of respiratory depression in postanesthesia care unit, postoperative extubation time, opioid-related adverse events within 24 hours, and Visual Analog Scale pain scores at 30 minutes, 4 hours, 8 hours, and 24 hours postextubation. Results: This study received approval from the Medical Ethics Committee of Deyang People’s Hospital, Deyang, China, on April 16, 2025 (approval 2025-03-009-K01). Participant recruitment is anticipated to be completed by December 2025. Data analysis, manuscript preparation, and submission for publication are expected to be completed by February 2026. Conclusions: The successful completion of this trial will generate evidence regarding whether oliceridine enhances recovery quality while reducing opioid-related complications compared to sufentanil in patients undergoing hysteroscopy under general anesthesia. Trial Registration: Chinese Clinical Trial Registry ChiCTR2500104024; https://www.chictr.org.cn/showproj.html?proj=275501 International Registered Report Identifier (IRRID): DERR1-10.2196/84521

21 September 2025 in JMIR Preprints
Verified
Preprint
Open access
YSYuHang Shou
YuHang Shou
JLJianSheng Luo
JianSheng Luo
XZXianJie Zhang
XianJie Zhang
WZWenHu Zhai
WenHu Zhai
JHJia Han
Jia Han
BACKGROUND Hysteroscopy, the gold standard for diagnosing and treating intrauterine pathologies, has shown substantial increase in its adoption in clinical practice. Nevertheless, early postoperative pain and opioid-related adverse effects remain critical determinants of recovery quality. Oliceridine—a novel G protein-biased μ-opioid receptor agonist—demonstrates an improved therapeutic range over conventional opioids in preliminary studies. OBJECTIVE This study aims to evaluate whether oliceridine enhances recovery quality while reducing opioid-related complications compared to sufentanil in patients undergoing hysteroscopy under general anesthesia. METHODS This single-center randomized controlled trial will enroll 120 patients undergoing hysteroscopy under general anesthesia with 1:1 randomization to sufentanil- or oliceridine-based analgesia. The primary outcome is early recovery quality assessed by the 15-item Quality of Recovery scale at 24 hours after the surgery, while secondary outcomes include hemodynamic fluctuations during induction, total intraoperative opioid consumption and supplemental bolus frequency, proportion requiring vasoactive agents, incidence of respiratory depression in postanesthesia care unit, postoperative extubation time, opioid-related adverse events within 24 hours, and Visual Analog Scale pain scores at 30 minutes, 4 hours, 8 hours, and 24 hours postextubation. RESULTS This study received approval from the Medical Ethics Committee of Deyang People’s Hospital, Deyang, China, on April 16, 2025 (approval 2025-03-009-K01). Participant recruitment is anticipated to be completed by December 2025. Data analysis, manuscript preparation, and submission for publication are expected to be completed by February 2026. CONCLUSIONS The successful completion of this trial will generate evidence regarding whether oliceridine enhances recovery quality while reducing opioid-related complications compared to sufentanil in patients undergoing hysteroscopy under general anesthesia. CLINICALTRIAL Chinese Clinical Trial Registry ChiCTR2500104024; https://www.chictr.org.cn/showproj.html?proj=275501 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/84521

21 January 2025 in International Journal of Anesthesia and Clinical Medicine
Verified
Journal Article
Open access
PDF file
YSYu-Hang Shou
Yu-Hang Shou
JLJian-Sheng Luo
Jian-Sheng Luo
WZWen-Hu Zhai
Wen-Hu Zhai
XZXian-Jie Zhang
Xian-Jie Zhang
JHJia Han
Jia Han
This prospective randomized double-blind trial compared the efficacy and safety of 0.3 mg/kg versus 0.5 mg/kg esketamine combined with propofol in 120 young and middle-aged patients (ASA I–II, 20–45 years) undergoing combined gastroscopy and colonoscopy. Participants were randomized to 0.3 mg/kg (Esk0.3, n = 60) or 0.5 mg/kg esketamine (Esk0.5, n = 60). The Esk0.5 group required significantly less propofol (126.1 ± 38.5 mg vs. 154.5 ± 25.8 mg, P < 0.001) and shorter induction time (51.5 ± 8.3 s vs. 58.6 ± 9.1 s, P < 0.001) compared to Esk0.3. However, postoperative recovery time (17.6 ± 4.8 min vs. 13.2 ± 5.8 min, P < 0.001) and operating room exit time (28.7 ± 7.6 min vs. 21.5 ± 4.1 min, P < 0.001) were prolonged in the Esk0.5 group. No differences were observed in procedure duration or patient satisfaction. The Esk0.5 group exhibited higher heart rates at gastroscope withdrawal (83.55 ± 5.34 vs. 80.46 ± 7.45 bpm, P = 0.01), alongside increased adverse events including secretions (13.3% vs. 3.3%, P = 0.037) and diplopia (13.3% vs. 3.3%, P = 0.037). Both groups showed high rates of involuntary twitching (28.3% vs. 35.0%). Esketamine 0.5 mg/kg reduces propofol requirements and accelerates induction but prolongs recovery and increases specific adverse events, necessitating individualized dosing and postoperative monitoring to optimize safety.

21 January 2025 in International Journal of Anesthesia and Clinical Medicine
Verified
Journal Article
Open access
PDF file
YSYu-Hang Shou
Yu-Hang Shou
JSJian-Sheng Luo Shou
Jian-Sheng Luo Shou
XSXian-Jie Zhang Shou
Xian-Jie Zhang Shou
WSWen-Hu Zhai Shou
Wen-Hu Zhai Shou
JSJia Han Shou
Jia Han Shou
Background: Total hip arthroplasty (THA) is a common procedure for end-stage hip disorders, yet postoperative pain management remains challenging due to opioid-related complications, particularly in elderly patients vulnerable to respiratory depression and delirium. Multimodal analgesia strategies are increasingly prioritized to mitigate these risks. Esketamine, an NMDA receptor antagonist with opioid-sparing and anti-neuroinflammatory properties, shows promise in enhancing analgesia while reducing adverse effects. Preliminary studies suggest its efficacy in lowering postoperative pain and delirium risk, though optimal dosing in elderly THA populations remains unclear. This study aimed to evaluate the analgesic efficacy and safety of different dosages of esketamine combined with sufen-tanil for patient-controlled intravenous analgesia (PCIA) in elderly patients undergoing total hip arthroplasty. Methods: In this randomized, prospective, double-blind trial, 120 elderly patients were randomly divided into three groups: the control group (Group S, n = 40) received sufentanil 2 μg/kg; the experimental group SE1 ( n = 40) received sufentanil 1.5 μg/kg combined with esketamine 1 mg/kg; and the experimental group SE2 ( n = 40) received sufentanil 1 μg/kg combined with esketamine 2 mg/kg. Primary outcomes included resting and movement-associated Visual Analogue Scale (VAS) scores at 4, 8, 12, 24, and 48 h postoperatively. Secondary outcomes encompassed Ramsay Sedation Scale (RSS) scores, Quality of Recovery-15 (QoR-15) scores at 48 h, time to first walk, the number of patients requiring remedial analgesia, and adverse events (nausea/vomiting, hallucinations, pruritus, delirium, dizziness). Results: The SE1 and SE2 groups demonstrated significantly superior analgesic efficacy compared to the S group across all outcomes. Resting and movement-associated VAS scores were significantly lower in both esketamine-combined groups at all postoperative time points (4, 8, 12, 24, and 48 h; P < 0.05). Sedation levels (Ramsay scores) were dose-dependently enhanced with esketamine. Group SE2 exhibited higher sedation scores than Group S at 24 h (P < 0.01) and 48 h (P < 0.05). The QoR-15 scores at 48 h were significantly higher in Groups SE1 and SE2 compared to Group S (P < 0.001). Time to first walk was shorter in Groups SE1 and SE2 than in Group S (P < 0.001). No significant differences were observed in the requirement for rescue analgesia between groups. Adverse events showed a significant reduction in postoperative delirium (POD) incidence (P < 0.01) and nausea/vomiting (P < 0.05) in Groups SE1 and SE2 compared to Group S, with no significant differences in dizziness, hallucinations, or pruritus. Conclusion: This randomized controlled trial demonstrated that esketamine combined with reduced-dose sufentanil significantly improved postoperative analgesia and recovery outcomes in elderly patients undergoing THA.